Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5ClN2O |
| Molecular Weight | 168.58 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(O1)C=CC(Cl)=C2
InChI
InChIKey=YGCODSQDUUUKIV-UHFFFAOYSA-N
InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)
| Molecular Formula | C7H5ClN2O |
| Molecular Weight | 168.58 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Zoxazolamine is a centrally acting muscle relaxant. It decreased striatal dopamine metabolism without affecting striatal dopamine concentrations. More specifically, Zoxazolamine was shown to decrease striatal dopamine turnover without directly affecting dopamine synthesis, catabolism, reuptake, or release. It is the IK(Ca) channel opener. It was approved for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases. Later, it was submitted for the drug's use as a uricosuric agent to treat gout. It was withdrawn from the market due to hepatotoxicity.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0042417 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6467036 |
|||
Target ID: CHEMBL4305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10712246 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Flexin Approved UseZoxazolamine was indicated as a uricosuric agent to treat gout. Launch Date1956 |
|||
| Primary | Flexin Approved UseZoxazolamine was indicated for the relief of muscle spasm in conditions such as musculoskeletal disorders and neurological diseases Launch Date1956 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
7.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/13571254/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
ZOXAZOLAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
250 mg 4 times / day multiple, oral Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years |
Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (acute, 1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hepatitis | acute, 1 patient Disc. AE |
250 mg 4 times / day multiple, oral Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 40 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Functional coupling of ATP-binding cassette transporter Abcb6 to cytochrome P450 expression and activity in liver. | 2015-03-20 |
|
| Halogen, hydrogen and electrostatic interactions in 2-amino-5-chloro-1,3-benzoxazol-3-ium nitrate and 2-amino-5-chloro-1,3-benzoxazol-3-ium perchlorate. | 2010-09 |
|
| Bioenhancers: Revolutionary concept to market. | 2010-04 |
|
| 12-(4-Chloro-phen-yl)-9,9-dimethyl-9,10-dihydro-8H-benzo[a]xanthen-11(12H)-one. | 2010-02-06 |
|
| 9,9-Dimethyl-12-(4-nitro-phen-yl)-9,10-dihydro-12H-benzo[a]xanthen-11(8H)-one. | 2009-11-21 |
|
| 9,9-Dimethyl-12-phenyl-8,9-dihydro-12H-benzo[a]xanthen-11(10H)-one. | 2009-11-07 |
|
| Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. | 2009-08 |
|
| Anti-clastogenic effect of magnolol-containing Hange-koboku-to, Dai-joki-to, Goshaku-san, and Magnoliae Cortex on benzo(a)pyrene-induced clastogenicity in mice. | 2009-07 |
|
| Inhibitory effect of magnolol on Trp-P-2-induced DNA damage in various organs in mice. | 2009-07 |
|
| Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR). | 2009-02-04 |
|
| Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain. | 2008-10 |
|
| Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. | 2008-09 |
|
| Alterations in xenobiotic metabolism in the long-lived Little mice. | 2007-08 |
|
| The environmental estrogen, nonylphenol, activates the constitutive androstane receptor. | 2007-08 |
|
| Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution. | 2007-06-28 |
|
| Surgical correction of fixed kyphosis. | 2007-06 |
|
| Hepatoprotective potential of Aloe barbadensis Mill. against carbon tetrachloride induced hepatotoxicity. | 2007-05-22 |
|
| Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PParalpha and CAR, the constitutive androstane receptor, in mouse liver. | 2007 |
|
| Gender-specific induction of cytochrome P450s in nonylphenol-treated FVB/NJ mice. | 2006-10-15 |
|
| Isolation, structure elucidation and in vivo hepatoprotective potential of trans-tetracos-15-enoic acid from Indigofera tinctoria Linn. | 2006-10 |
|
| Effect of some biologically interesting substituted tetrahydro-1,4-oxazines on drug metabolising enzymes and on inflammation. | 2005-10 |
|
| Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. | 2005-08-30 |
|
| Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. | 2004-10-18 |
|
| Functional and molecular identification of intermediate-conductance Ca(2+)-activated K(+) channels in breast cancer cells: association with cell cycle progression. | 2004-07 |
|
| Characteristics and a functional implication of Ca(2+)-activated K(+) current in mouse aortic endothelial cells. | 2004-01 |
|
| Inhibition of endothelium-dependent vasorelaxation by extracellular K(+): a novel controlling signal for vascular contractility. | 2004-01 |
|
| Effect of novel anti-inflammatory ethanolamine derivatives with antioxidant properties on drug metabolising enzymes. | 2003-09-25 |
|
| Effect of p-amino-diphenyl ethers on hepatic microsomal cytochrome P450. | 2003-09 |
|
| Unexpected down-regulation of the hIK1 Ca2+-activated K+ channel by its opener 1-ethyl-2-benzimidazolinone in HaCaT keratinocytes. Inverse effects on cell growth and proliferation. | 2003-01-31 |
|
| Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. | 2003-01-03 |
|
| Moricizine, an antiarrhythmic agent, as a potent inhibitor of hepatic microsomal CYP1A. | 2002-12 |
|
| Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. | 2001-11 |
|
| In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. | 2001-10 |
|
| Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. | 2001-06 |
|
| Hepatoprotective activity of indigtone--a bioactive fraction from Indigofera tinctoria Linn. | 2001-06 |
|
| Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. | 2001-03 |
|
| Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo. | 2001-01 |
|
| Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. | 2000-03 |
|
| In-vivo effects of itraconazole on hepatic mixed-function oxidase. | 1988-02 |
|
| Effect of benzopyrone derivatives on drug activity and metabolism. | 1986-10-01 |
|
| The murine aromatic hydrocarbon responsiveness locus: a comparison of receptor levels and several inducible enzyme activities among recombinant inbred lines. | 1986-03 |
|
| Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides. | 1974-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14492563
0.5 gm daily dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14648123
Mouse aortic endothelial cells were loaded with 0.5 uM Ca2+ in the pipette and current measured at 50 and −50 mV during repetitive ramps and the corresponding I/V curves constructed. 100 uM of zoxazolamine activated the K(Ca) current.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:04 GMT 2025
by
admin
on
Mon Mar 31 17:45:04 GMT 2025
|
| Record UNII |
9DOW362Q29
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C921
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D015049
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
24995
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
SUB00192MIG
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
C152966
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
6103
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
m11669
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL472566
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
9DOW362Q29
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
DTXSID1045245
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
524
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
100000078820
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
2876
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
61-80-3
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
Zoxazolamine
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY | |||
|
200-519-4
Created by
admin on Mon Mar 31 17:45:04 GMT 2025 , Edited by admin on Mon Mar 31 17:45:04 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |